{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:02:21Z","timestamp":1791414141074,"version":"4.3.3"},"reference-count":28,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2014,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Oxazolidinones represent a new class of antituberculosis drugs that exert their function by inhibiting protein synthesis. Here, we compared the activities of three oxazolidinones, linezolid, PNU-100480, and AZD5847, against latent tuberculosis using a simple model employing the streptomycin-starved\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Mycobacterium tuberculosis<\/jats:named-content>\n            strain 18b. The\n            <jats:italic>in vitro<\/jats:italic>\n            drug susceptibility results showed that the three oxazolidinones had a bacteriostatic effect against actively growing bacilli but potent bactericidal activity against nonreplicating cells. In the murine model of latent infection with\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">M. tuberculosis<\/jats:named-content>\n            18b, the efficacy of the three compounds varied greatly. Indeed, AZD5847 or its prodrug exhibited no activity or only modest activity, respectively, after 2 months of treatment, whereas both linezolid and PNU-100480 were effective against latent bacilli in mice and showed promising outcomes in combination therapy with rifampin. Moreover, the potency of PNU-100480 was significantly greater than that of linezolid, making it an attractive drug candidate in the development of new combination therapies for latent tuberculosis.\n          <\/jats:p>","DOI":"10.1128\/aac.02410-14","type":"journal-article","created":{"date-parts":[[2014,3,25]],"date-time":"2014-03-25T05:38:21Z","timestamp":1395725901000},"page":"3217-3223","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":58,"title":["<i>In Vitro<\/i>\n            and\n            <i>In Vivo<\/i>\n            Activities of Three Oxazolidinones against Nonreplicating Mycobacterium tuberculosis"],"prefix":"10.1128","volume":"58","author":[{"given":"Ming","family":"Zhang","sequence":"first","affiliation":[{"name":"Global Health Institute, Ecole Polytechnique F\u00e9d\u00e9rale de Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Sala","sequence":"additional","affiliation":[{"name":"Global Health Institute, Ecole Polytechnique F\u00e9d\u00e9rale de Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Dhar","sequence":"additional","affiliation":[{"name":"Global Health Institute, Ecole Polytechnique F\u00e9d\u00e9rale de Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Vocat","sequence":"additional","affiliation":[{"name":"Global Health Institute, Ecole Polytechnique F\u00e9d\u00e9rale de Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasan K","family":"Sambandamurthy","sequence":"additional","affiliation":[{"name":"AstraZeneca India Pvt., Ltd., Hebbal, Bangalore, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreevalli","family":"Sharma","sequence":"additional","affiliation":[{"name":"AstraZeneca India Pvt., Ltd., Hebbal, Bangalore, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwendolyn","family":"Marriner","sequence":"additional","affiliation":[{"name":"Tuberculosis Research Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Balasubramanian","sequence":"additional","affiliation":[{"name":"AstraZeneca India Pvt., Ltd., Hebbal, Bangalore, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart T.","family":"Cole","sequence":"additional","affiliation":[{"name":"Global Health Institute, Ecole Polytechnique F\u00e9d\u00e9rale de Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","volume-title":"Global tuberculosis report 2012","author":"World Health Organization","year":"2012","unstructured":"World Health Organization. 2012. Global tuberculosis report 2012. World Health Organization Geneva, Switzerland. (http:\/\/www.who.int\/tb\/publications\/global_report\/en\/)."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2011.06330.x"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm800379d"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M102966200"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00414-07"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki148"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl298"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00009509"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01182-08"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01179-10"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1086\/655471"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200904-0611OC"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030479"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01903-13"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00076-10"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00228-09"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200806-892OC"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1201964"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00821-10"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01125-12"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201012-1949OC"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.64.6.2062-2069.1996"},{"key":"e_1_3_3_24_2","volume-title":"Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology","author":"Balasubramanian V","year":"2011","unstructured":"BalasubramanianVGaonkarSSolapureSSambandamurthyVShandilRMaheshKSharmaSKaurPDeepthiRSubbulakshmiVRamyaVRamachandranVReddyJGiridharJDeshpandeABharathSKumarNBalganeshMNandiVWrightIMelnickD. 2011. AZD5847, an oxazolidinone for the treatment of tuberculosis: pre-clinical studies, poster F1-1364. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_3_25_2","first-page":"1265","volume-title":"Abstr 52nd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology","author":"Louie A","year":"2012","unstructured":"LouieABrownDFilesKSwiftMFikesSDrusanoG. 2012. Pharmacodynamics of PNU-100480 (U, Sutezolid), a new oxazolidinone, in combination with its active metabolite in the killing of Mycobacterium tuberculosis (Mtb) in an in vitro hollow fiber infection model (HFIM), abstr A-414, p 1265. Abstr 52nd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2003.07.033"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06227-11"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2958.2002.03242.x"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01189-07"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02410-14","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02410-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:44:54Z","timestamp":1645483494000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02410-14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["10.1128\/AAC.02410-14"],"URL":"https:\/\/doi.org\/10.1128\/aac.02410-14","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"2014-01-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-03-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-05-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}